2019, Chronic Pain, Epilepsy and Pharmaceutical

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

Veriheal

FEBRUARY 21, 2023

Opioid Abuse and Drug Overdose Deaths Are Higher in States With Restrictive MMJ Policies Despite ongoing political debates about the limitations of medical marijuana programs, a 2019 study published in the Journal of Patient-Centered Research and Reviews provided further evidence of how MMJ-restrictive states inadvertently impact their patients.

Access

Access Patients Chronic Pain Conditions

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al. Robert Schatz.

Pharmaceutical

Pharmaceutical Clinical Trials Therapy Treatment

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials

Clinical Trials Pharmaceutical Research and Development Therapy

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical

Pharmaceutical Clinical Trials Research and Development Therapy

Cannabis & Coronavirus – A Pharmacist’s Perspective

CannaTech

APRIL 1, 2020

When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design, synthesis, formulation, dispensing and testing of drugs and the clinical and social aspects of pharmacy. And most especially in these times, cannabis is used effectively to treat anxiety.

Supply Chain

Supply Chain Chronic Pain Pharmaceutical Patients

Revamping Texas’ Medical Cannabis Program Is the Key to Ending the State’s Opioid Crisis

Veriheal

MAY 31, 2022

With a worsening opioid situation and an emerging acceptance of medical cannabis, the Lone Star State has a unique opportunity to develop a successful medical marijuana (MMJ) program for its millions of residents battling chronic pain and numerous other conditions. A 2019 study found that 76% of patients in the U.S.

Programs

Programs Chronic Pain Treatment Conditions

Medicinal Cannabis Use Approved in French Polynesia

Veriheal

JANUARY 12, 2023

The law also permits the agricultural production of cannabis and hemp for industrial purposes, with a heavy emphasis on pharmaceutical crops. . Approximately 3,000 patients who suffer from debilitating conditions like chronic pain and epilepsy will partake in the project, which is due to end in March 2023.

Medicine

Medicine Chronic Pain Consumption Cannabis

NORML 2019 Legislative Report

Cannabis Law Report

DECEMBER 30, 2019

This report contains a detailed summary of 2019’s federal and state legislative victories.” 2019 has been an unprecedented year for the passage of state-level marijuana law reforms. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019.

Legislation

Legislation Patients Access Banking

REPEAT – AgraFlora Organics Completes UK Home Office Controlled Drug Handling License Inspection

Cannabis Law Report

DECEMBER 14, 2019

12, 2019 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) ( PU31.F VANCOUVER, British Columbia, Dec. The UK medicinal cannabis market value is forecast to reach almost US$1.3 billion by 2024.

Pharmaceutical

Pharmaceutical Chronic Pain Patients Epilepsy

The Latin American Cannabis Landscape – Part Two: Regulated Markets and Patient Access

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. This statistic accounts for medicines treating patients with epilepsy, anxiety, depression, chronic pain, and other illnesses. This article has primarily offered a small dose of the pharmaceutical side of the medical cannabis market in Latin America.

Access

Access Patients Pharmaceutical Education

Press Release: UK Leading British Medical Cannabis and CBD Company, Cannaray, Announces First UK Medical Cannabis Prescription

Cannabis Law Report

JANUARY 15, 2020

million Series A funding round in 2019, Cannaray has announced the fulfilment of its first UK patient prescription as the company continues to grow, becoming one of UK’s largest Medical Cannabis and CBD company. . Following a £7.8 Cannaray today announces the fulfilment of its first Medical Cannabis prescription in the UK.

CBD

CBD Epilepsy Chronic Pain Treatment

Lighting Up Florida’s Medical Marijuana PEOPLE: The Front Lines

Cannabis Law Report

JUNE 26, 2019

For those of you in the dark about Florida’s Medical Marijuana Program, I will be lighting up the dim corners of Florida: The Nation’s Fastest-Growing Medical Marijuana Market , according to The Miami New Times on May 2, 2019. Dr. Weiner is certified in Interventional Pain Management and Physical Medicine and Rehabilitation.

Marijuana

Marijuana Agriculture Research and Development Education

The State of Medical Cannabis in the UK

CannaTech

MARCH 29, 2019

While the amendments to the scheduling of marijuana for medical use were intended to increase access, in reality, only patients suffering from epilepsy, MS, side effects of chemotherapy and chronic pain are eligible. Visit us at CannaTech Tel Aviv 2019, Booth 42 to find out more.

Chronic Pain

Chronic Pain Access Patients Food

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Using a content analysis approach, we investigated articles about medicinal cannabis from 2000 to the end of 2019 in the Medical Journal of Australia, Australian Doctor , Medical Observer , Australian Journal of General Practice , Australian Family Physicia n , and Australian Medicine. Refractory paediatric epilepsy. Cancer pain.

Research and Development

Research and Development Medicine Access Media

Study Suggests That THC is More Efficient at Providing Symptomatic Relief for Nausea Than CBD

Veriheal

JULY 5, 2021

The self-reported data was logged between June 6, 2016, and July 8, 2019. The UNM researchers noted that, since nausea is just one symptom, CBD may be a better option for relieving the symptoms associated with other types of medical conditions, such as epilepsy and chronic pain. Motion sickness.

THC

THC CBD Treatment Cannabinoids

A Patient’s Guide to CBD and Drug Interactions

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible. Drug metabolism reviews 46.1

CBD

CBD THC Conditions Medicine

What Does Cannabis Legalization Look Like in the UK?

Veriheal

OCTOBER 1, 2020

America: Lee Carrol Broker was sentenced to life in prison without the possibility of parole on the groups that he grew three dozen cannabis plants intended for personal use since he suffered from chronic pain as a result of being 75 years old and a disabled veteran. . During 2019, it was estimated that the UK had a difference of -$45.8

Legalization

Legalization Oil Medicine Media

Portugal Special Guest Post: João Taborda da Gama, “One Year of Medical Cannabis in Portugal”

Cannabis Law Report

JULY 15, 2019

Fortunately, the way the medical cannabis law was regulated by the Government provided more clarity and certainty on the regulatory framework: in January 2019, the Government published Decree Law 8/2019, detailing the requirements under which medical cannabis could be marketed, prescribed and sold.

Medicine

Medicine Clinical Trials Patients Access

Biggest Business Challenges for the Cannabis Industry in 2022

The Joint Blog

FEBRUARY 24, 2022

The District of Columbia and Eleven states legalized the adoption of the product in 2019. recognized the product as a medical drug to cure post-traumatic stress disorder, epilepsy, chronic pain, arthritis, and Alzheimer’s disease. The Industry in North America stood at USD 19.78 The state medical cannabis law in the U.S.

Business

Business Research and Development Chronic Pain Policy

Press Release: UK’s Cannaray raises £7.8m Series A in major European CBD gambit

Cannabis Law Report

SEPTEMBER 10, 2019

September 9, 2019. Instead, CBD is fast garnering a reputation in the medical world as a potentially soothing treatment for conditions like arthritis, epilepsy , mental stress, or muscle pain, even as for certain forms of cancer.). UK’s Cannaray raises £7.8m Series A in major European CBD gambit. Richard Martyn-Hemphill.

CBD

CBD Wellness and Beauty Banking Epilepsy

What seniors need to know before getting a medical marijuana card

The Cannigma

AUGUST 29, 2021

The AARP, explaining its 2019 policy change, stated that its decision was based on “the growing body of research suggesting marijuana may be helpful in treating certain medical conditions and symptoms.”. Across the United States, the most common health condition treated with medical cannabis is chronic pain.

Blood Pressure

Blood Pressure Marijuana Conditions Sleep

A Patient’s Guide to CBD and Drug Interactions

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible. 2019): 3. [3]

CBD

CBD THC Conditions Medicine

Loophole Allows Australians To Import Prescribed Medical Cannabis

Cannabis Law Report

APRIL 22, 2019

Mr Plamandon said he successfully brought Thai-prescribed cannabis products into WA to treat his chronic pain on April 8. million chronic pain sufferers were predicted to get access to the drug in 2019. million chronic pain sufferers were predicted to get access to the drug in 2019.

Chronic Pain

Chronic Pain Medicine Conditions Access

Meritas Law Firms Worldwide Article: Global Cannabis Industry: The Essential Primer

Cannabis Law Report

OCTOBER 17, 2019

When the first physical stores opened six months later in April 2019, legal recreational cannabis sales in the province more than doubled online sales from the previous two months. In June 2019, the country released its regulations for other forms of cannabis, from topicals to extracts to edibles, which become legal on October 17, 2019.

Law

Law Seed-To-Sale Hemp Recreational

Medical Cannabis Brief

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Trending Sources

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis & Coronavirus – A Pharmacist’s Perspective

Revamping Texas’ Medical Cannabis Program Is the Key to Ending the State’s Opioid Crisis

Medicinal Cannabis Use Approved in French Polynesia

NORML 2019 Legislative Report

REPEAT – AgraFlora Organics Completes UK Home Office Controlled Drug Handling License Inspection

The Latin American Cannabis Landscape – Part Two: Regulated Markets and Patient Access

Press Release: UK Leading British Medical Cannabis and CBD Company, Cannaray, Announces First UK Medical Cannabis Prescription

Lighting Up Florida’s Medical Marijuana PEOPLE: The Front Lines

The State of Medical Cannabis in the UK

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Study Suggests That THC is More Efficient at Providing Symptomatic Relief for Nausea Than CBD

A Patient’s Guide to CBD and Drug Interactions

What Does Cannabis Legalization Look Like in the UK?

Portugal Special Guest Post: João Taborda da Gama, “One Year of Medical Cannabis in Portugal”

Biggest Business Challenges for the Cannabis Industry in 2022

Press Release: UK’s Cannaray raises £7.8m Series A in major European CBD gambit

What seniors need to know before getting a medical marijuana card

A Patient’s Guide to CBD and Drug Interactions

Loophole Allows Australians To Import Prescribed Medical Cannabis

Meritas Law Firms Worldwide Article: Global Cannabis Industry: The Essential Primer

Stay Connected